Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|17|7|824-849

ISSN： 1389-4501

Source： Current Drug Targets, Vol.17, Iss.7, 2016-06, pp. : 824-849

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Molecular Targets in Malignant Pleural Mesothelioma Treatment

By  

Current Drug Targets, Vol. 10, Iss. 12, 2009-12 ,pp. : 1235-1244

Bentham Science Publishers

Access to resources Recommend Favorite

Management Options for Malignant Pleural Mesothelioma: Clinical and Cost Considerations

By Goudar Ranjit K.  

Drugs, Vol. 67, Iss. 8, 2007-01 ,pp. : 1149-1165

Adis International

Access to resources Recommend Favorite

Pemetrexed/cisplatin worth it in malignant pleural mesothelioma

By  

Inpharma, Vol. 1, Iss. 1627, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Current chemotherapeutic treatment of malignant pleural mesothelioma

By Nowak Anna K   Byrne Michael J   Millward Michael J   Alvarez John M   Robinson Bruce WS  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 12, 2004-12 ,pp. : 2441-2449

Informa Healthcare

Access to resources Recommend Favorite

Malignant pleural mesothelioma: current treatments and emerging drugs

By Belli Carmen   Fennell Dean   Giovannini Monica   Gaudino Giovanni   Mutti Luciano  

Expert Opinion on Emerging Drugs, Vol. 14, Iss. 3, 2009-09 ,pp. : 423-437

Informa Healthcare

Access to resources Recommend Favorite